Our Portfolio
UNC Health Ventures invests in innovative healthcare companies addressing critical challenges across the healthcare landscape. Our portfolio includes companies spanning medical devices, healthcare IT, diagnostics, biopharma, and healthcare services that are working to improve patient outcomes, enhance care delivery, strengthen health system operations, and reduce the overall cost of healthcare.
Advancing biologic and small-molecule therapies for patients with serious diseases and unmet medical needs.
Visit Arrivo Bio
Provides diagnostic platforms that support newborn screening and pediatric testing for rare diseases.
Visit Baebies
Uses AI-powered clinical data abstraction to improve quality reporting, analytics, and care operations.
Visit Carta Healthcare
Enables healthcare organizations to manage cybersecurity, compliance, and third-party risk across complex vendor ecosystems.
Visit Censinet
AI-powered medical coding platform that automates workflows and improves revenue cycle performance.
Visit Fathom
Creates minimally invasive therapies for gastrointestinal diseases using magnetic compression technology.
Visit GI Windows Surgical
Supplies sterile compounding and pharmaceutical manufacturing services to healthcare providers.
Visit Leiters
Delivers solid-state cooling technology for healthcare, life sciences, and temperature-sensitive applications.
Visit Phononic
Provides a secure enterprise AI platform that transforms organizational knowledge into trusted, searchable insights.
Visit Pryon
Delivers an intelligent decongestion management (IDM) solution for acute decompensated heart failure patients.
Visit Reprieve
Develops neuromodulation therapies aimed at treating chronic pain and neurological disorders.
Visit Synaptrix
Advances fluorescence-guided imaging agents that help surgeons visualize cancer during procedures.
Visit Vergent Bioscience
Delivers rapid fluid resuscitation technology for patients experiencing shock and other critical conditions.
Visit 410 Medical
Prior Investments
Assets acquired by Jazz Pharmaceutical in 2014.
Learn more
Strategic growth investment made by Thoma Bravo.
Learn more
Acquired by Norwest Venture Partners in 2018.
Learn more
